Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Rational Dosage Regimen: Maintenance Dose and Loading Dose

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Elements Crucial for Effective Psychotherapy

Elements Crucial for Effective Psychotherapy

Research has highlighted several critical factors that influence the effectiveness of psychotherapy, such as the therapeutic alliance, the therapist, and the client.
The Therapeutic Alliance
The therapeutic alliance refers to the relationship between the therapist and the client. The alliance strengthens when the therapist and the client engage in a nurturing, supportive, trusting, empathetic, and respectful relationship, improving therapeutic outcomes. Therapists must monitor this relationship...

Dosage Regimens: Designs and Approaches

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026

Same author

From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma.

Blood·2026

Same author

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

American journal of hematology·2026

Same author

Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Blood advances·2026

Same author

To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma.

Haematologica·2026

Same author

Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursors.

Cancer genetics·2026

Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025

Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025

Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025

Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

The present: optimizing therapy--too much or too little?

Nancy L Bartlett¹

¹Siteman Cancer Center, Washington University, St. Louis, MO 63110, USA. nbartlet@dom.wustl.edu

Hematology. American Society of Hematology. Education Program

|January 18, 2011

Summary

This summary is machine-generated.

Prognosis for classical Hodgkin lymphoma (HL) improves, but better prognostic markers are needed. Current treatment decisions balance risks of "too much" or "too little" therapy, with new agents offering hope for relapsed cases.

Related Experiment Videos

Last Updated: Jun 5, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Area of Science:

Oncology
Hematology
Clinical Trials

Background:

Classical Hodgkin lymphoma (HL) prognosis has improved significantly over 20 years due to less toxic therapies.
Current challenges involve identifying prognostic markers for therapy reduction in favorable subsets and new strategies for high-risk patients.

Purpose of the Study:

To address the need for better prognostic markers in classical Hodgkin lymphoma.
To optimize treatment de-escalation for favorable risk groups and escalation for high-risk patients.
To inform ongoing clinical trial strategies and treatment debates in HL.

Main Methods:

Review of current treatment approaches and clinical trial designs for newly diagnosed HL.
Analysis of interim restaging PET/CT in guiding therapy adjustments.
Discussion of treatment debates, including consolidative radiotherapy and escalated BEACOPP regimens.

Main Results:

Ongoing trials utilize interim PET/CT to guide de-escalation for early responders and escalation for suboptimal responders.
Debates persist regarding consolidative radiotherapy in early-stage HL and escalated BEACOPP in advanced-stage disease.
Treatment decisions remain challenging, balancing risks of overtreatment and undertreatment.

Conclusions:

Despite improved outcomes, precise prognostic markers are crucial for personalized therapy in classical Hodgkin lymphoma.
Interim PET/CT is a key tool in ongoing trials for tailoring treatment intensity.
New agents offer promising options for patients who do not respond to first-line therapy, but initial treatment decisions require careful consideration of available data.